KAS
ATOS icon

Kestra Advisory Services’s Atossa Therapeutics ATOS Stock Holding History

Kestra Advisory Services’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-700
Closed -$34K – 2014
2021
Q3 		$34K Buy
+700
New +$40.7K ﹤0.01% 2093
2021
Q2 		– Sell
-913
Closed -$29K – 1997
2021
Q1 		$29K Buy
+913
New +$33.4K ﹤0.01% 1841

Other funds holding ATOS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Kestra Advisory Services's ATOS Position: Q4 2021 in Review

Kestra Advisory Services sold out of Atossa Therapeutics (ATOS) in Q4 2021, closing a stake of 700 shares — an estimated $34K sold.

Kestra Advisory Services first reported a position in ATOS in Q1 2021 and held it in 2 quarters. The position peaked at $34K in Q3 2021. 91 funds tracked by Wall St. Rank hold ATOS as of Q4 2021.

  • Kestra Advisory Services reported no remaining Atossa Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Kestra Advisory Services sold 700 Atossa Therapeutics shares in Q4 2021, an estimated $34K.
  • Kestra Advisory Services first reported a position in Atossa Therapeutics in Q1 2021 and held it in 2 quarters.
  • Kestra Advisory Services's Atossa Therapeutics position peaked at $34K in Q3 2021.
  • 91 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q4 2021.

Based on Kestra Advisory Services's 13F filing for Q4 2021, filed 20 Jan 2022.